CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management

March 17, 2025

By Krish Patel, MD
Saurabh Dahiya, MD, FACP

Opinion

Video

Panelists discuss the comparison between clinical trial results and real-world outcomes for chimeric antigen receptor T-cell (CAR T) therapies like liso-cel and axi-cel. Clinical trials have shown promising efficacy and manageable safety profiles for both therapies in treating certain blood cancers. However, real-world evidence continues to emerge through ongoing clinical use and registry data collection.

EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy

EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL

EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL

EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL

Now Viewing

EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management

EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection

EP: 7.Personalizing CAR T: Making the Right Call for Each Patient

EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL

EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?

EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease

EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care

Video content above is prompted by the following:

How do the efficacy and safety outcomes of liso-cel and axi-cel in clinical trials compare to what you have observed in real-world practice?
Are there specific patient populations or clinical scenarios where you find the trial data align—or diverge—from real-world experiences with CAR T therapy?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!